HER2 or not HER2: That is the question

[1] ALBAIN K, 2001, P AN M AM SOC CLIN, V20, pA24

[2] ALBAIN K, 2004, 27 SAN ANT BREAST CA

[3] Baum M, 2003, Cancer, V98, P1802

[4] Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) : 46 - 53

[5] Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 3676 - 3685

[6] Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741 [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) : 1431 - 1439

[7] A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) : 1081 - 1092

[8] Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:: Evidence from a phase III randomized trial [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) : 3808 - 3816

[9] THE ROGERS,WILL PHENOMENON - STAGE MIGRATION AND NEW DIAGNOSTIC-TECHNIQUES AS A SOURCE OF MISLEADING STATISTICS FOR SURVIVAL IN CANCER [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (25) : 1604 - 1608

[10] A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (19) : 1793 - 1802

[1] ALBAIN K, 2001, P AN M AM SOC CLIN, V20, pA24

[2] ALBAIN K, 2004, 27 SAN ANT BREAST CA

[3] Baum M, 2003, Cancer, V98, P1802

[4] Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) : 46 - 53

[5] Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 3676 - 3685

[6] Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741 [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) : 1431 - 1439

[7] A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) : 1081 - 1092

[8] Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:: Evidence from a phase III randomized trial [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) : 3808 - 3816

[9] THE ROGERS,WILL PHENOMENON - STAGE MIGRATION AND NEW DIAGNOSTIC-TECHNIQUES AS A SOURCE OF MISLEADING STATISTICS FOR SURVIVAL IN CANCER [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (25) : 1604 - 1608

[10] A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (19) : 1793 - 1802